Literature DB >> 2109643

Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man.

W Martin1, G Koselowske, H Töberich, T Kerkmann, B Mangold, J Augustin.   

Abstract

The lysine salt of d,l-2-(4-isobutylphenyl)-propionic acid (ibuprofen lysine) was administered as a single oral dose of 500 mg by means of commercially available coated tablets (Imbun).* To assess the absolute bioavailability of ibuprofen after its oral application as a lysine salt, intravenous injections of ibuprofen solutions containing 200 mg and 400 mg of the drug served as reference application. In a partially randomized cross-over design, 8 healthy male volunteers received three different single dose administrations which were separated by wash-out periods of 4 days each. Ibuprofen plasma concentrations were determined by HPLC using direct injection, pre-column enrichment and column switching techniques. From the results of intravenous injections one can deduce linear ibuprofen pharmacokinetics within the considered dosage range, with corresponding AUC0-infinity values of 3786 micrograms * min ml-1 and 7260 micrograms * min ml-1 for the 200 mg and 400 mg doses, respectively. The values of plasma clearances as well as those of different volumes of distribution showed remarkable constancy after evaluation from both intravenous injections. The absorption of orally administered ibuprofen lysine proved to be rapid, resulting in a mean peak plasma level (Cmax) of 31 micrograms ml-1 ibuprofen and in a mean time to peak (tmax) of 45 min. The absolute bioavailability of ibuprofen amounts to 102.7 per cent, indicating a complete absorption of ibuprofen when administered as its lysine salt. Drug tolerability was excellent for the oral administration of ibuprofen lysine as well as for the intravenous treatments with ibuprofen free acid. Only mild and transient adverse drug reactions such as mild burning or dragging sensation during injection or mild redness at the site of injection were reported.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109643     DOI: 10.1002/bdd.2510110311

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  13 in total

Review 1.  Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever.

Authors:  Howard S Smith; Bryan Voss
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

2.  Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen.

Authors:  Diana Højmark Omkvist; Birger Brodin; Carsten Uhd Nielsen
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 3.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

4.  Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate.

Authors:  J Lötsch; U Muth-Selbach; I Tegeder; K Brune; G Geisslinger
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

5.  Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.

Authors:  H Cheng; J D Rogers; J L Demetriades; S D Holland; J R Seibold; E Depuy
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

Review 6.  Topical ocular delivery of NSAIDs.

Authors:  Munish Ahuja; Avinash S Dhake; Surendra K Sharma; Dipak K Majumdar
Journal:  AAPS J       Date:  2008-04-25       Impact factor: 4.009

7.  Ibuprofen impairs allosterically peroxynitrite isomerization by ferric human serum heme-albumin.

Authors:  Paolo Ascenzi; Alessandra di Masi; Massimo Coletta; Chiara Ciaccio; Gabriella Fanali; Francesco P Nicoletti; Giulietta Smulevich; Mauro Fasano
Journal:  J Biol Chem       Date:  2009-09-03       Impact factor: 5.157

8.  Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically-based modeling as a candle in the dark.

Authors:  Brian Cicali; Tao Long; Sarah Kim; Rodrigo Cristofoletti
Journal:  Br J Clin Pharmacol       Date:  2020-05-13       Impact factor: 4.335

9.  A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.

Authors:  Min Ye; Swati Nagar; Ken Korzekwa
Journal:  Biopharm Drug Dispos       Date:  2016-04       Impact factor: 1.627

10.  Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers.

Authors:  Peter M Dewland; Sandie Reader; Phillip Berry
Journal:  BMC Clin Pharmacol       Date:  2009-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.